# DUR-928 in Patients With Alcoholic Hepatitis

> **NCT03917407** · PHASE2 · COMPLETED · sponsor: **Craig James McClain** · enrollment: 43 (actual)

## Conditions studied

- Alcoholic Hepatitis

## Interventions

- **DRUG:** DUR-928 (Moderate AH)
- **DRUG:** DUR-928 (Severe AH)

## Key facts

- **NCT ID:** NCT03917407
- **Lead sponsor:** Craig James McClain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2023-09-24
- **Final completion:** 2023-09-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03917407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03917407, "DUR-928 in Patients With Alcoholic Hepatitis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03917407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*